| Identification | Back Directory | [Name]
COMPOUND 52 | [CAS]
212779-48-1 | [Synonyms]
NG-52
COMPOUND 52
NG-52, >98%
NG 52 (Compound 52 )
NG52; COMPOUND52;NG-52;COMPOUND-52
2-(2-HYDROXYETHYLAMINO)-6-(3-CHLORANILINO)-9-ISOPROPYLPURINE
2-(2-HYDROXYETHYLAMINO)-6-(3-CHLOROANILINO)-9-ISOPROPYLPURINE
2-[[6-(3-chloroanilino)-9-propan-2-ylpurin-2-yl]amino]ethanol
2-(2-Hydroxyethylamino)-6-(3-chloroanilino)-9-isopropylpurine, NG-52
2-((6-((3-chlorophenyl)aMino)-9-isopropyl-9H-purin-2-yl)aMino)ethanol
2-[[6-[(3-Chlorophenyl)amino]-9-(1-methylethyl)-9H-purin-2-yl]amino]ethanol
Ethanol, 2-[[6-[(3-chlorophenyl)amino]-9-(1-methylethyl)-9H-purin-2-yl]amino]- | [Molecular Formula]
C16H19ClN6O | [MDL Number]
MFCD02179196 | [MOL File]
212779-48-1.mol | [Molecular Weight]
346.81 |
| Chemical Properties | Back Directory | [Boiling point ]
587.7±60.0 °C(Predicted) | [density ]
1.42±0.1 g/cm3(Predicted) | [storage temp. ]
Keep in dark place,Sealed in dry,2-8°C | [solubility ]
methylene chloride: 50 mg/mL, clear, colorless
| [form ]
powder
| [pka]
14.54±0.10(Predicted) | [color ]
white to off-white
|
| Hazard Information | Back Directory | [Description]
NG 52 is a tri-substituted purine that binds to the ATP-binding site of yeast cyclin-dependent kinases, inhibiting Cdc28p and Pho85p (IC50s = 7 and 2 μM, respectively). It is ineffective against the yeast kinases Kin28p, Srb10, and Cak1p. NG 52 is cell permeable and inhibits the growth of S. cerevisiae (GI50 = 30 μM). It is an analog of purvalanol A , a potent inhibitor of mammalian cyclin-dependent kinases. | [Uses]
NG 52 is a potent, cell-permeable, selective, ATP-compatible and orally active Cdc28p and Pho85p kinase inhibitor with IC50s of 7 μM and 2 μM, respectively. NG 52 also inhibits the activity of phosphoglycerate kinase 1 (PGK1) with an IC50 of 2.5 μM. NG 52 is inactive against yeast kinases Kin28p, Srb10, and Cak1p[1][2]. | [in vivo]
NG 52 (50-150 mg/kg; oral administration; daily; for 13 days) treatment dose-dependently suppresses the growth of glioma xenograft[2]. | Animal Model: | Female nu/nu mice (5-week-old) injected with glioma cells[2] | | Dosage: | 50 mg/kg, 100 mg/kg, 150 mg/kg | | Administration: | Oral administration; daily; for 13 days | | Result: | Dose-dependently suppressed the growth of glioma xenograft.
|
| [IC 50]
cdc2-cyclin B: 0.34 μM (IC50); Pho85p: 2 nM (IC50); Cdc28p: 7 μM (IC50); Phosphoglycerate kinase 1 (PGK1): 2.5 μM (IC50) | [References]
[1] ray NS, Wodicka L, Thunnissen AM et al. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science. 1998 Jul 24;281(5376):533-8. DOI:10.1126/science.281.5376.533
[2] Wen-Liang Wang, et al. Pharmacologically inhibiting phosphoglycerate kinase 1 for glioma with NG52. Acta Pharmacol Sin. 2020 Jul 31. DOI:10.1038/s41401-020-0465-8 |
|
| Company Name: |
D&C Chemicals
|
| Telephone: |
+86-21-58447131 |
| Website: |
www.chemicalbook.com/ShowSupplierProductsList16963/0_EN.htm |
| Company Name: |
SPIRO PHARMA
|
| Telephone: |
|
| Website: |
www.spiropharma.com.cn |
|